FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burd	den										
hours per response:	0.5										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kiener Peter A</u>					2. Issuer Name and Ticker or Trading Symbol Sucampo Pharmaceuticals, Inc. [ SCMP ]									all applicable) Director		g Person(s) to Issuer  10% Owner Other (specify		
(Last) (First) (Middle) 805 KING FARM BLVD, SUITE 550					3. Date of Earliest Transaction (Month/Day/Year) 12/31/2016									Officer (give title below)  Chief Scientific		below ntific Officer		
(Street)  ROCKV			20850 (Zip)		4. If	If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv Line) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
		,		on-Deriv	ative	Sec	uritie	s Ac	auired	L Die	sposed o	f. or F	Renefi	cially	Owne	-d		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			ction	ion 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securitie	rities Acquired (A) of (D) (Instr. 3, 4		5. Am and 5) Secur Bene Owne Repo		ount of ties cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock, Class A (ESPP) <sup>(1)</sup> 12/31/2				2016	2016		Code	v	287	(D) A		0.46 <sup>(2)</sup>	(Instr. 3 and 4) 46 <sup>(2)</sup> 1,036		D			
Table II - I		Derivat (e.g., pomed on Date,	ive S uts, c	/e Securities Acquits, calls, warrants		mber rative rities ired r osed	A V 28/ sired, Disposed of, options, convertib  6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Date Expiration Date			or Beneficia		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- 1. The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c).
- 2. In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock.

/s/ Peter Kiener

01/06/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.